{
  "thread": {
    "uuid": "3e0bbf1b6d7f10e40f09780e6496d61071f554f9",
    "url": "https://www.defenseworld.net/2025/08/14/hc-wainwright-has-pessimistic-outlook-of-aldx-q3-earnings.html",
    "site_full": "www.defenseworld.net",
    "site": "defenseworld.net",
    "site_section": "https://www.defenseworld.net",
    "site_categories": [
      "media"
    ],
    "section_title": "Defense World",
    "site_title": "Defense World",
    "title": "HC Wainwright Has Pessimistic Outlook of ALDX Q3 Earnings",
    "title_full": "HC Wainwright Has Pessimistic Outlook of ALDX Q3 Earnings",
    "published": "2025-08-14T08:40:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 38342,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "3e0bbf1b6d7f10e40f09780e6496d61071f554f9",
  "url": "https://www.defenseworld.net/2025/08/14/hc-wainwright-has-pessimistic-outlook-of-aldx-q3-earnings.html",
  "ord_in_thread": 0,
  "author": "Defense World Staff",
  "published": "2025-08-14T08:40:00.000+03:00",
  "title": "HC Wainwright Has Pessimistic Outlook of ALDX Q3 Earnings",
  "text": "Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX – Free Report ) – Investment analysts at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report released on Monday, August 11th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings of ($0.16) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.13) EPS, FY2027 earnings at $0.43 EPS and FY2028 earnings at $0.83 EPS. Separately, Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. Get Our Latest Analysis on ALDX ALDX opened at $5.37 on Wednesday. The firm has a market cap of $321.66 million, a price-to-earnings ratio of -6.32 and a beta of 0.76. Aldeyra Therapeutics has a 12 month low of $1.14 and a 12 month high of $7.20. The stock has a fifty day moving average price of $4.30 and a 200-day moving average price of $4.25. Aldeyra Therapeutics ( NASDAQ:ALDX – Get Free Report ) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. In other news, insider Stephen Machatha sold 22,073 shares of the business’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the completion of the transaction, the insider directly owned 221,799 shares of the company’s stock, valued at approximately $1,142,264.85. The trade was a 9.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link . Insiders own 9.60% of the company’s stock. Several hedge funds have recently added to or reduced their stakes in the business. Panagora Asset Management Inc. increased its position in Aldeyra Therapeutics by 42.8% during the 2nd quarter. Panagora Asset Management Inc. now owns 72,059 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 21,605 shares in the last quarter. Rhumbline Advisers increased its position in Aldeyra Therapeutics by 2.7% during the 2nd quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 2,018 shares in the last quarter. Intech Investment Management LLC increased its position in Aldeyra Therapeutics by 27.6% during the 2nd quarter. Intech Investment Management LLC now owns 29,983 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 6,477 shares in the last quarter. King Wealth Management Group acquired a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $46,000. Finally, Geode Capital Management LLC increased its position in Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock valued at $4,392,000 after buying an additional 8,769 shares in the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds. ( Get Free Report )Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance",
    "Health",
    "Science and Technology"
  ],
  "topics": [
    "Economy, Business and Finance->financial service",
    "Economy, Business and Finance->business reporting and performance",
    "Science and Technology->scientific research",
    "Science and Technology->economics"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [
    "https://www.marketbeat.com/stocks/NASDAQ/ALDX/",
    "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=ALDX",
    "https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat",
    "https://www.marketbeat.com/stocks/NASDAQ/ALDX/earnings/",
    "http://www.sec.gov/Archives/edgar/data/1341235/000095017025108210/xslF345X05/ownership.xml",
    "https://marketbeat.com/stocks/NASDAQ/ALDX/",
    "https://www.marketbeat.com/stocks/NASDAQ/ALDX/earnings",
    "https://www.wallstreetzen.com/newsletters/zen-ratings",
    "https://marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=ALDX",
    "https://wallstreetzen.com/newsletters/zen-ratings?ticker=ALDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat",
    "http://sec.gov/Archives/edgar/data/1341235/000095017025108210/xslF345X05/ownership.xml",
    "https://www.marketbeat.com/stocks/NASDAQ/ALDX",
    "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx",
    "https://marketbeat.com/stocks/NASDAQ/ALDX/earnings/"
  ],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [
      {
        "name": "M. Caufield",
        "sentiment": "none"
      }
    ],
    "locations": [],
    "organizations": [
      {
        "name": "Aldeyra Therapeutics",
        "sentiment": "none",
        "tickers": []
      },
      {
        "name": "Wall Street Zen",
        "sentiment": "none",
        "tickers": [
          {
            "ticker": null,
            "exchange": null
          }
        ]
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-08-14T08:42:43.319+03:00",
  "updated": "2025-08-14T08:53:58.000+03:00"
}